HOME >> BIOLOGY >> NEWS
'Auditory Scene Analysis' Helps Find Mates

SEATTLE -- It's a problem faced by people joining noisy parties and by midshipman fish seeking mates: How to cut through the racket and find Mr. Right?

Now Cornell University biologists, who became underwater disc jockeys to study a homely fish that hums, say they have a clue as to how mate selection works. The auditory portion of the midbrain uses the acoustic qualities of all the noise to isolate one signal it is programmed to recognize as potentially interesting.

The biologists' research applies only to midshipman fish, but it could, they say, also be relevant to people.

"Neuroscientists call this auditory scene analysis," says Andrew H. Bass, Cornell professor of neurobiology and behavior who will present his group's findings June 25 at the International Congress on Acoustics-Acoustical Society of America meeting in Seattle. "It's really very similar to the cocktail party effect."

In a way, midshipman fish have more problems than people at loud parties. Only some of the male midshipman hum (See "Humming Fish Facts," attached), and those males are hiding in cavitylike nests they have excavated under rocks. All the humming males together sound like a huge hive of bees or a squadron of motor boats, and a female midshipman fish has to choose one nest in which to deposit her eggs. When a humming male succeeds in attracting a female, he fertilizes her eggs, which adhere to the rocky ceiling of his nest. The female leaves forever, and the male resumes humming in hopes of attracting another female with more eggs.

Wondering how the female fish find the right males, the Cornell biologists examined the structure and function of midshipman brains. From earlier studies with Robert Baker at the New York University Medical School, Bass knew that a part of the midshipman male brain, called the hindbrain, contains neurons that constitute a kind of vocal pacemaker. Like a rhythm generator, the pacemaker tells the sound-generating
'"/>

Contact: Roger Segelken
hrs2@cornell.edu
607-255-9736
Cornell University News Service
25-Jun-1998


Page: 1 2 3

Related biology news :

1. Software Helps Decipher Genomes Of Higher Organisms
2. Nutrition Therapy Helps Patients Emotionally, Research Shows
3. ASU Professor Helps In Fight To Protect Japanese Pika Habitat
4. Whitehead Study Supports Existence Of Ancient RNA World, Helps Provide Insight Into Early Evolution Of Life
5. Duke Study Helps Explain How Cells Divvy Up Genes During Reproduction
6. Transplanted Skeletal Muscle Mimics Heart Muscle; Helps Failing Heart Pump, Duke Researchers Say
7. Security Code Helps Immune Cells Attack Foe And Spare Self
8. NASA Research Helps Map Protein Structures -- Key In The Development Of New Disease-Fighting Drugs
9. UF Researchers Innovative Fence Helps Control Sand Flies
10. Interleukin-12 Helps Control Mycobacterium Avium Infection
11. Purdue Research Helps Keep Phosphorus Out Of Surface Water

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Auditory Scene Analysis Helps Find Mates

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: